New Targets from the Treatment of Parkinson’s Disease
As mentioned in previous updates, analysis of two publicly available Parkinson’s Disease (“PD”) datasets using C4XD’s proprietary target discovery technology Taxonomy3® has identified multiple novel disease associated genes in discrete patient sub-groups that could potentially provide an opportunity in stratified medicine. Informatic analysis of proprietary genes discovered with Taxonomy3®, together with known genetic susceptibility genes, has flagged new pathways relevant to the disease aetiology: identification of such disease-relevant pathways is a pivotal step in drug discovery.
During 2018, we nominated and initiated the first drug discovery evaluation stage programme in PD from this analysis and continue to work through the other novel drug targets from the genes we have discovered to provide the biological validation ahead of initiating further drug discovery programmes. As an approach to further maximise the value from these novel findings in PD in May 2018 we announced a collaboration with e-Therapeutics. This collaboration is based on leveraging the power of e-Therapeutics’ proprietary Network-Driven Drug Discovery (“NDD”) platform with C4XD’s Taxonomy3® technology. e-Therapeutics has applied its pioneering NDD platform to PD with the addition of C4XD’s novel and proprietary results from Taxonomy3® to derive further new insights into the corresponding cellular mechanisms in order to understand their interplay and centrality in the pathology of the disease. It is hoped that this work will ultimately lead to the identification of new treatment strategies, molecular targets and ultimately, novel drugs. The collaboration has progressed very well with an update expected to be announced in the near future.